Phase II Single-arm Clinical Study of the Efficacy and Safety of Cadonilimab in Combination With Lenvatinib Neoadjuvant Therapy for Patients With High-risk Renal Carcinoma Indicating Partial Nephrectomy
Latest Information Update: 24 Nov 2023
At a glance
- Drugs Cadonilimab (Primary) ; Lenvatinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 24 Nov 2023 New trial record